Celldex 制药 CLDX

Anthony S. Marucci is Founder, President and CEO since September 2008, and Director since December 2008. He has an M.B.A. from Columbia University and an M.H.L. from Brown University. He was Former Vice President, Chief Financial Officer, Treasurer and Secretary at Celldex. He was Treasurer at Medarex and held senior financial positions at Medarex. He served on the Board of Directors of Genenta Science S.p.A. and is on the Board of Trustees of BioNJ Inc.

Tibor Keler, Ph.D. is Founder, Executive Vice President and Chief Scientific Officer since 2014. He has a Ph.D. in Microbiology from the University of Pennsylvania. He was Senior Vice President and Chief Scientific Officer at Celldex from March 2008 to July 2014. He was Vice President, Research and Discovery and Chief Scientific Officer at Celldex from May 2003 to March 2008. He was Senior Director of Preclinical Development and Principal Scientist at Medarex from September 1993 to March 2004.

Elizabeth Crowley is Senior Vice President and Chief Product Development Officer since 2016. She has a B.S. in Chemistry with a concentration in Business from Boston College. She was Senior Vice President, Product Development at Celldex from July 2014 to August 2016. She was Vice President, Clinical Development at Celldex from 2009 to July 2014. She held several senior level roles at CuraGen Corporation and held several roles in clinical research and project management at Bayer Corporation.

Sam Martin is Senior Vice President, Chief Financial Officer and Secretary since 2017. He has an M.B.A. from Boston University, a B.S. from Skidmore College, and is a Certified Public Accountant. He was Vice President, Finance, Senior Director of Finance, and Director of Financial Reporting, Planning and Analysis at Celldex. He held several former roles at Alseres Pharmaceuticals, Inc., most recently as Director of Finance and Corporate Compliance. He also held several former roles at Ernst & Young LLP, most recently serving as Audit Manager. On July 10, 2026, Sam Martin, Senior Vice President and Chief Financial Officer of Celldex Therapeutics, Inc., notified the Company of his plans to retire effective on or about March 31, 2027. Mr. Martin joined the Company in April 2009 and has served as Chief Financial Officer since July 2017.

Denice Torres is Director since June 2025. She has a Bachelor of Science from Ball State University, J.D. from Indiana University, M.B.A. from University of Michigan, and M.A. Study of Happiness from Centenary University. She has been Chief Executive Officer at The Ignited Company since 2017. She was Chief Strategy and Transformation Officer at Johnson & Johnson, Global Medical Device Business, President at Johnson & Johnson McNeil Consumer Healthcare, President at Johnson & Johnson Janssen Pharmaceuticals, Neuroscience, and held various executive positions at Eli Lilly and Company. She has served on the Board of Directors of 2seventybio, Glaukos Corporation, Karuna Therapeutics, Surface Oncology, and Bluebird bio, Inc.

Harry H. Penner, Jr. is Chair since January 1997. He has a B.A. from the University of Virginia, a J.D. from Fordham University, and an L.L.M. in International Law from New York University. He has served as Board and Chairman of AVANT, Chairman and Chief Executive Officer of Nascent BioScience, LLC, President, Chief Executive Officer and Vice Chairman of Neurogen Corporation, Executive Vice President and General Counsel at Novo Nordisk A/S, and Executive Vice President for North America. He was Former Chair of BioCT, Connecticut Technology Council, and Connecticut Board of Governors of Higher Education. He is currently Chair of NeuroCyte Therapeutics, Inc.

Garry Neil, M.D. is Director since June 2022. He has a B.S. from the University of Saskatchewan and an M.D. from the University of Saskatchewan College of Medicine. He completed postdoctoral clinical training in internal medicine and gastroenterology at the University of Toronto and a postdoctoral research fellowship at the Research Institute of Scripps Clinic. He has served as Chief Executive Officer, Chairman of the Board, Senior Scientific Adviser, and Chief Scientific Officer at Avalo Therapeutics. He was Partner at Apple Tree Partners, Corporate Vice President of Science & Technology at Johnson & Johnson, Former Group President at Johnson & Johnson Pharmaceutical Research and Development, Former Vice President of Research & Development at Merck KGaA/EMD Pharmaceuticals, and Former Vice President of Clinical Research at AstraZeneca and Astra Merck. He has also served on the Board of Directors of Arena Pharmaceuticals, Zura Bio Limited, GTX, Inc., Hackensack Meridian Medical School, TransCelerate Biopharma, Reagan Udall Foundation for the FDA, and National Institutes of Health. He was Former Chairman of Science and Regulatory Executive Committee and the PhRMA Foundation Board at Pharmaceutical Research and Manufacturers Association.

Herbert J. Conrad is Director since March 2008. He has B.S. and M.S. degrees from the Brooklyn College of Pharmacy and an honorary Doctorate in Humane Letters from Long Island University. He was President of the U.S. Pharmaceuticals Division at Hoffmann-La Roche, Inc. from 1982 to 1993. He was Former Director at Matinas BioPharma Holdings, Inc. and Arbutus Biopharma Corporation. He was an Advisor at Seaver Autism Center at Mount Sinai Hospital. He was Former Chairman of the Board of Directors at Pharmasset, Inc., GenVec, Inc. and Bone Care International, Inc. He was Former Director and Co-Founder of Reliant Pharmaceuticals, Inc.

Mr. Teri Lawyer is Senior Vice President and Chief Commercial Officer since 2025. She has a Masters of Business Administration from Duke University Fuqua School of Business and a Bachelor of Science Degree in Linguistics from Georgetown University. She was Principal and Owner at Thera Lifescience Advisors LLC, Strategic Advisor, EVP and Chief Commercial Officer at Dexcom Corporation, and held general management and commercial leadership roles at Johnson & Johnson Corporation. She also held roles at McKinsey & Company as Associate Principal, Engagement Manager, and Consultant.

Freddy Jimenez is Senior Vice President and General Counsel since 2021. He has a B.A. in Biology and Certificate in the Legal Studies Program from Brandeis University and his legal training and JD from the Rutgers School of Law-Newark. He was Vice President, Law and Compliance at Celldex from February 2016 to December 2020. He held roles at Johnson & Johnson as Assistant General Counsel, Senior Counsel, General Attorney, and FDA Liaison. He was Associate in the Food and Drug Practice at Akin Gump Strauss Hauer & Feld LLP.

Diane C. Young, M.D. is Senior Vice President, Chief Medical Officer since 2019. She has an A.B. in Biochemical Sciences from Harvard University and an M.D. from Harvard Medical School. She completed medical training in internal medicine at Johns Hopkins Hospital and Vanderbilt University Hospital and completed a fellowship in medical oncology at Dana-Farber Cancer Institute. She was Vice President, Chief Medical Officer at GTx, Inc. from July 2015 until February 2019. She held roles at Novartis Oncology including Vice President, Head of Oncology Clinical Development and Medical Affairs, Latin America and Canada, Vice President, Global Head of Medical Affairs, Oncology Business Unit, and Vice President, Global Head of Clinical Development Phase 2/3, Oncology Business Unit from 2002 to June 2015. She held roles at R.W. Johnson Pharmaceutical Research Institute including Vice President for Global Development and Senior Director, Clinical Research and Development from 1993 to 2002. She held roles at Sandoz Research Institute as Director of Clinical Research, Cytokine Development Unit and Associate Medical Director from 1991 to 1993. She was Assistant Director, Clinical Investigation II at Hoffmann-LaRoche, Inc. from 1988 to 1990.

Ronald Pepin, Ph.D. is Senior Vice President and Chief Business Officer since 2011. He has a B.A. from Tufts University and a Ph.D. in Genetics from Georgetown University. He was Vice President at Shire Pharmaceuticals from June 2010 to April 2011. He was Senior Vice President, Business Development at Medarex from August 2000 to December 2009. He was Former Executive Director of External Science and Technology at Bristol-Myers Squibb Company.